| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Mannan-binding lectin serine protease 2; Mannose-binding protein-associated serine protease 2; MASP-2; MBL-associated serine protease 2; |
| Entrez GeneID | 10747; |
| WB Predicted band size | 75kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human MASP2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于MASP2抗体的代表性文献及其摘要概括：
---
1. **文献名称**: *Targeting mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury*
**作者**: Schwaeble WJ 等
**摘要**: 研究证明MASP2抗体可抑制补体凝集素途径，减轻小鼠心肌和肠道缺血再灌注损伤，降低炎症反应和组织损伤，提示其治疗潜力。
---
2. **文献名称**: *Narsoplimab in patients with hemolytic uremic syndrome: a phase 3 trial*
**作者**: Rambaldi A 等
**摘要**: 临床试验显示，MASP2单抗narsoplimab能显著改善非典型溶血性尿毒症综合征(aHUS)患者的肾脏功能及血小板计数，验证了MASP2在补体介导血栓性疾病中的关键作用。
---
3. **文献名称**: *MASP2-mediated complement activation exacerbates COVID-19 hyperinflammation*
**作者**: Ali YM 等
**摘要**: 研究发现COVID-19重症患者体内MASP2水平升高，使用特异性抗体阻断MASP2可减少补体过度激活和细胞因子风暴，为免疫调节治疗提供新方向。
---
4. **文献名称**: *Inhibition of MASP-2 modulates the lectin pathway in a primate model of sepsis*
**作者**: Takahashi M 等
**摘要**: 在灵长类脓毒症模型中，MASP2抗体通过选择性抑制凝集素途径减轻全身性炎症反应和多器官衰竭，支持其作为脓毒症辅助治疗的可行性。
---
这些研究覆盖了MASP2抗体在基础机制、疾病模型及临床转化中的应用，核心聚焦于补体凝集素途径的调控及治疗价值。
The MASP2 antibody targets Mannose-Binding Lectin-Associated Serine Protease 2 (MASP-2), a key enzyme in the lectin pathway of the complement system. MASP-2 is synthesized primarily in the liver and circulates as a proenzyme bound to pattern recognition molecules like MBL, ficolins, or collectins. Upon pathogen or damaged cell recognition, MASP-2 is activated, cleaving complement components C4 and C2 to form the C3 convertase (C4b2a), driving downstream immune responses. Dysregulation of MASP-2 is linked to autoimmune diseases, inflammatory disorders (e.g., ischemia-reperfusion injury, thrombotic microangiopathy), and COVID-19 complications due to excessive complement activation.
MASP2 antibodies, often monoclonal, inhibit MASP-2 activity to modulate complement-mediated inflammation. Preclinical studies highlight their therapeutic potential in reducing tissue damage in models of renal injury, stroke, and transplant rejection. Notably, narsoplimab (OMS721), a humanized anti-MASP-2 antibody, has shown promise in clinical trials for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and IgA nephropathy. Its selective inhibition of the lectin pathway offers advantages over broad-spectrum complement inhibitors, preserving critical immune functions. Research continues to explore MASP2 antibodies in diverse complement-driven pathologies, balancing efficacy with safety in immune modulation.
×
